📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Pfizer Ltd Q3 Net Profit Rises 11% YoY to ‡141.8 Cr; Revenue Up 20%
Pfizer Limited reported a strong 20% year-on-year growth in revenue from operations, reaching ‡645.03 crore for the quarter ended December 31, 2025. Despite an exceptional charge of ‡58.20 crore related to workforce restructuring and new labor code provisions, net profit grew by 11% to ‡141.84 crore. The company entered a strategic agreement with Cipla for the distribution of four key brands, leading to a one-time separation cost of ‡39.58 crore. Overall, the operational performance remains robust with a significant 19.7% improvement in nine-month profitability compared to the previous year.
Key Highlights
Revenue from operations grew 19.9% YoY to ‡645.03 crore from ‡537.99 crore in the previous year.
Net profit increased 11.2% YoY to ‡141.84 crore, overcoming a ‡58.20 crore exceptional charge.
Exceptional items include ‡39.58 crore for personnel separation following a distribution deal with Cipla for four brands.
A provision of ‡18.62 crore was recorded to account for the impact of the Government's New Labour Codes.
Nine-month net profit stands at ‡522.61 crore, up significantly from ‡436.66 crore in the corresponding period last year.
💼 Action for Investors
Investors should focus on the strong double-digit revenue growth and the strategic partnership with Cipla which aims to optimize distribution for key brands. The one-time exceptional costs are non-recurring, indicating healthy underlying operational margins.
Pfizer Partners with Cipla for Exclusive Marketing of 4 Key Brands for 5 Years
Pfizer Limited has entered into a strategic 5-year exclusive agreement with Cipla Limited for the marketing and distribution of four key brands: Corex Dx, Corex LS, Dolonex, and Neksium in India. Under this arrangement, Pfizer will continue to manufacture and supply these medicines while leveraging Cipla's extensive distribution network to enhance market reach. Notably, the company announced this shift will result in a reduction of its own field force, with the associated financial impact to be disclosed in upcoming quarterly results. This move indicates a strategic pivot towards a leaner operating model for these specific legacy brands.
Key Highlights
Exclusive 5-year marketing and distribution agreement signed with Cipla Limited for four major brands.
Brands included in the deal are Corex Dx, Corex LS, Dolonex, and Neksium.
Pfizer Limited will retain all manufacturing and supply responsibilities for the products.
The agreement will lead to a reduction in Pfizer's field force, with severance or transition costs to be reported later.
No upfront consideration was exchanged; commercial terms are based on ongoing supply and marketing arrangements.
💼 Action for Investors
Investors should monitor the next financial statement for one-time restructuring costs related to the field force reduction. Long-term value depends on whether Cipla's distribution scale can drive enough volume growth to offset the change in margin structure.